What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Single dose (Part A) or Repeat-dose (Part B), subcutaneous injection(s) of RE104 for Injection”In the company’s words, NCT07489651 on ClinicalTrials.gov
- Tested for
- Adjustment Disorder, Generalized Anxiety Disorder
- Main trialPhase 2
- “The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.”In the company’s words, NCT07002034 on ClinicalTrials.gov
Other drugs for Adjustment Disorder
- Psilocybin therapyPsyence Australia Pty Ltd · Phase 2
- RanquilonValenta Pharm JSC · Marketed (Phase 4 trial)
Coming up2
- Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- Jul 2027Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovCompletion date moved: 2026-11 to 2027-04 · ClinicalTrials.gov NCT07002034
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Apr 2027 | RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | |
| Phase 2Recruiting | Jul 2027 | RE104 Safety and Efficacy Study in Generalized Anxiety Disorder | |
| Phase 2Completed | 22 May 2025 | RE104 Safety and Efficacy Study in Postpartum Depression | |
| Phase 1Completed | 28 May 2025 | RE104 Clinical Lactation Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026